Review on Medusa®:: a polymer-based sustained release technology for protein and peptide drugs

被引：38

作者：

Chan, Y-P ^{[1
]}

Meyrueix, R. ^{[1
]}

Kravtzoff, R. ^{[1
]}

Nicolas, F. ^{[1
]}

Lundstrom, K. ^{[1
]}

机构：

[1] Flamel Technol, F-69693 Venissieux, France

来源：

EXPERT OPINION ON DRUG DELIVERY | 2007年 / 4卷 / 04期

关键词：

animal models; clinical trials; polymer-protein complexes; slow release; LIPID MICROPARTICLES; MICROSPHERES; DELIVERY; FORMULATION; NANOPARTICLES; CYLINDERS; HYDROGELS; SYSTEM; MODEL;

D O I：

10.1517/17425247.4.4.441

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The polymer-based Medusa(R) system (Flamel Technologies) has been designed for slow release of therapeutic proteins and peptides. The Medusa II consists of a poly L-glutamate backbone grafted with hydrophobic alpha-tocopherol molecules, creating a colloidal suspension of nanoparticles (10 - 50 nm) in water. The sustained drug release is based on reversible drug interactions with hydrophobic nanodomains within the nanoparticles. In vivo, it is suggested that the therapeutic protein is displaced by endogenous proteins present in physiological fluids, leading to a slow drug release. The peak concentration is dramatically decreased and the protein release substantially extended. The Medusa technology has been applied to subcutaneous injection for several therapeutic proteins, such as IL-2 and IFN-alpha(2b)', in animal models (rats, dogs, monkeys) and clinical trials in renal cancer (IL-2) and hepatitis C (IFN-alpha(2b)) patients.

引用

页码：441 / 451

页数：11

共 38 条

[1] Efficacy and pharmacokinetics of site-specific cefazolin delivery using biodegradable implants in the prevention of post-operative wound infections [J].